<DOC>
	<DOCNO>NCT00712101</DOCNO>
	<brief_summary>The purpose study examine whether intracoronary abciximab bolus application subsequent 12 hour intravenous infusion addition primary percutaneous coronary intervention beneficial patient STEMI comparison standard i.v . bolus application respect 90-day mortality , reinfarction new congestive heart failure .</brief_summary>
	<brief_title>Abciximab i.v . Versus i.c . ST-elevation Myocardial Infarction</brief_title>
	<detailed_description>In patient acute ST-elevation myocardial infarction ( STEMI ) primary percutaneous coronary intervention ( PCI ) prefer reperfusion regimen , perform experienced operator timely manner . Nevertheless , myocardial damage immediately terminate successful epicardial reperfusion primary PCI . Current strategy direct improve myocardial tissue perfusion , impair approximately 50 % patient prognostic impact . Adjunctive intravenous abciximab administration establish therapy improve coronary microcirculation reduce major cardiac adverse events.5-10 In randomized clinical trial intravenous abciximab administration study . Clinical trial show early administration result higher preinterventional TIMI-flow subsequent improve perfusion post PCI . However , pool analysis effect mortality . As door-to-balloon-times get short current trial , early abciximab administration require treatment prehospital setting , pose substantial logistic obstacle . Another option might intracoronary abciximab bolus administration result high local platelet inhibitor concentration . This might favorable dissolution thrombus microemboli subsequent improve myocardial microcirculation , reduction no-reflow , infarct size . Currently , limit clinical experience efficacy intracoronary abciximab administration mainly restrict case report , retrospective registry small randomized trial . In recently publish randomized clinical trial , able show intracoronary versus intravenous abciximab bolus administration beneficial effect occurrence no-reflow infarct size assess contrast-enhancement magnetic resonance imaging . This lead trend towards improve clinical outcome . The composite major adverse cardiac event rate , define death , reinfarction , target vessel revascularization , new congestive heart failure , 30 day follow-up 15.6 % intravenous 5.2 % intracoronary abciximab administration ( relative risk 3.00 ; 95 % confidence interval 0.94-10.80 ; p=0.06 ) . Currently , adequately power clinical trial ass effect intracoronary bolus comparison standard intravenous abciximab administration . Due general availability ease intracoronary administration treatment overwhelm potential clinical practice , much easy achieve logistically cumbersome prehospital interhospital transfer administration . In era evidence-based medicine , trial paramount importance achieve break-through abciximab use reduction high associate morbidity mortality STEMI patient .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>1 . Clinical symptom : Angina pectoris &lt; 12 hour Persistent angina &gt; 30 minute 2 . ECGcriteria STelevation myocardial infarction 12lead ECG : STsegment elevation &gt; 1mm ≥ 2 extremity lead and/or STsegment elevation &gt; 2mm ≥ 2 adjacent precordial lead 3 . Informed consent 1 . No informed consent 2 . Pregnancy 3 . Known allergy abciximab , ASA heparin 4 . Active peptic ulcus ventriculus duodeni 5 . Active , nonsuperficial bleeding 6 . History major surgery ( include intracranial intraspinal ) &lt; 4 week 7. active internal bleeding 8 . Cerebrovascular complication &lt; 2 year 9 . Known coagulation defect thrombocytopenia 10 . Arteriovenous malformation aneurysm 11 . Severe liver insufficiency , renal insufficiency require dialysis 12 . Uncontrolled hypertension , hypertensive retinopathy 13 . Vaskulitis 14 . Thrombolysis &lt; 12 h 15 . Participation another trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>infarction</keyword>
	<keyword>intervention</keyword>
	<keyword>stent</keyword>
	<keyword>abciximab</keyword>
	<keyword>platelet</keyword>
</DOC>